Frequently Asked Questions
The rapid introduction of COVID-19 in 2020 caused significant shifts in international healthcare trends and altered how markets operated in these unheard-of circumstances. However, researchers looked at the possibility of using induced pluripotent stem cells to treat coronavirus infections throughout the pandemic.
North America accounted for the highest share in the global induced pluripotent stem cell (IPSC) market.
Increasing cases of chronic diseases and the development of automated IPSC production processes are the major factors driving the market’s growth.
Manual production process had a major share in 2021 with around 78% of the market revenue share. Besides, it is also projected to witness the fastest growth.
The cell culture segment had a major share in the global market in 2021.